Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05623956 | Proteomics in Small Cell Lung Cancer(SCLC-OMICS) | unknown | — | 50 | Aalborg University HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02236910 | An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours | unknown | Phase 2 | 66 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06121752 | Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine Tumors(DNET) | unknown | N/A | 54 | Asian Institute of Gastroenterology, IndiaOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06586697 | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06558903 | Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)(HYPE) | unknown | — | 20 | University Hospital, BrestOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04524208 | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3(CABONEN) | unknown | Phase 2 | 45 | Karsten GavenisOTHER | 2 | Aug 13, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06540937 | Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06530797 | A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer | unknown | — | 2,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06520319 | Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma | unknown | Phase 1 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT04847505 | 68Ga-DOTA-TATE PET/CT Imaging in NETs | unknown | Phase 3 | 5,000 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT04562337 | SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC | unknown | Phase 2 | 67 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483919 | The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer | unknown | — | 228 | Jinming YuOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06372626 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | unknown | Phase 1 / Phase 2 | 93 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06440122 | The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs) | unknown | — | 100 | King's College Hospital NHS TrustOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06246630 | In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor | unknown | N/A | 20 | Ruijin HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05396118 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | unknown | Phase 2 | 15 | Rigshospitalet, DenmarkOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06406660 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT05443646 | Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients | unknown | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06402695 | Observational Study on GEP-and Pulm-NET Treated at FPG(ETNA-FPG) | unknown | — | 650 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06343428 | Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients(TAPIOCA) | unknown | — | 20 | European Institute of OncologyOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06400654 | PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC(NIRVANA) | unknown | — | 100 | European Institute of OncologyOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05359146 | Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)(Beta plus) | unknown | Early Phase 1 | 16 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06364046 | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | unknown | N/A | 56 | The Central Hospital of Lishui CityOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05254119 | DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS(REGISTURK-LUNG) | unknown | — | 6,000 | Mahmut GumusNETWORK | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06323265 | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer | unknown | — | 50 | Hebei Medical University Fourth HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06156020 | Outcome Analysis of Endoscopic Resection of Pituitary Adenomas | unknown | N/A | 500 | National Cheng-Kung University HospitalOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321692 | Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications | unknown | N/A | 100 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT05475210 | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | unknown | Phase 1 | 9 | Molecular Targeting Technologies, Inc.INDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05334290 | Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment(FiReNEN) | unknown | — | 400 | Massimo FalconiOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06159920 | Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors. | unknown | — | 800 | IRCCS San RaffaeleOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06293833 | Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan(ZORALCS) | unknown | N/A | 700 | University Hospital, AntwerpOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06229405 | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data | unknown | — | 8,200 | Seoul National University HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06267170 | A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer(SCLC) | unknown | — | 288 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 20, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06234553 | Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma(RIPA) | unknown | — | 200 | Beijing Tiantan HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT01763554 | Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014 | unknown | — | 115 | AHS Cancer Control AlbertaOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03084770 | Asymptomatic Small Pancreatic Endocrine Neoplasms.(ASPEN) | unknown | — | 1,000 | IRCCS San RaffaeleOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05296603 | Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 83 | Hunan Province Tumor HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06187740 | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | unknown | Phase 1 | 28 | Fudan UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05991180 | Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer | unknown | — | 160 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | unknown | Phase 3 | 194 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT05418907 | Exendin PET/CT for Imaging of Paragangliomas(ENTRAP) | unknown | — | 10 | Radboud University Medical CenterOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06155734 | Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green | unknown | — | 6 | Leiden University Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04985851 | To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS. | unknown | N/A | 90 | Shanghai Chest HospitalOTHER | 1 | Dec 1, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jan 31, 2025source: clinicaltrials